سعر ليفوبرايد 25مجم 30 قرص 2025

Levosulpiride 25 mg tablets, pack of 30 (3 strips of 10).

• Short-term treatment of dyspeptic syndrome (anorexia, bloating, epigastric discomfort, postprandial headache, heartburn, belching, diarrhoea, constipation) due to delayed gastric emptying from organic (e.g. diabetic gastroparesis, cancer) or functional factors, in patients not responding to other treatment.Population: AdultsCIMA - Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)
• Short-term symptomatic treatment of nausea and vomiting induced by anticancer drugs after failure of first-line treatment.Population: AdultsCIMA - Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)
• Short-term symptomatic treatment of vertigo, tinnitus, hearing loss and nausea associated with Meniere syndrome.Population: AdultsCIMA - Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)

• Very rare: drowsiness, parkinsonism, dyskinesia, tremor, dystonia, neuroleptic malignant syndrome. Frequency unknown: amenorrhoea, gynaecomastia, galactorrhoea, libido changes and hyperprolactinaemia (prolonged use), venous thromboembolism, neonatal withdrawal/extrapyramidal symptoms. Rare (class effect): QT prolongation and ventricular arrhythmias; very rare sudden death.International label, same formulation · CIMA - Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)

• Hypersensitivity; known history of epilepsy, manic states and the manic phase of manic-depressive psychosis; phaeochromocytoma (risk of hypertensive crisis); malignant breast disease (hyperprolactinaemia); pregnancy and breastfeeding; when stimulation of gastrointestinal motility is harmful (gastrointestinal haemorrhage, mechanical obstruction or perforation).International label, same formulation · CIMA - Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)

• Use with caution in patients with stroke risk factors (about threefold increase in cerebrovascular events seen with some atypical antipsychotics in dementia) and note increased mortality in elderly people with dementia treated with antipsychotics; levosulpiride is not authorised for dementia-related behavioural disorders.International label, same formulation · CIMA - Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)
• Neuroleptic malignant syndrome (hyperpyrexia, muscle rigidity, autonomic instability, altered consciousness) has been reported with neuroleptics - stop immediately; venous thromboembolism has been reported with antipsychotics; use with caution in cardiovascular disease or family history of QT prolongation; avoid alcohol; contains lactose.International label, same formulation · CIMA - Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)
• High doses may cause drowsiness, numbness or dyskinesia; patients should avoid driving or operating machinery.International label, same formulation · CIMA - Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)

• QT-prolonging medicinesConcomitant use of neuroleptics with QT-prolonging medicines increases the risk of cardiac arrhythmias.CIMA - Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)
• Medicines causing electrolyte disturbancesLevosulpiride should not be given with medicines that cause electrolyte disturbances.CIMA - Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)
• Anticholinergic, narcotic and analgesic drugsThese may antagonise the effects of levosulpiride on gastrointestinal motility.CIMA - Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)

• No adequate well-controlled studies in pregnancy; levosulpiride is contraindicated in pregnancy and must not be used when pregnancy is suspected or confirmed.International label, same formulation · CIMA - Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)
• Contraindicated during breastfeeding.International label, same formulation · CIMA - Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)

English text not available for this section.